Prevalence of Cardiovascular Risk Factors in Upper Vestibular Neuritis

Vestibular Neuritis Clinical Trial

— NEVRITE  

Official title:

Prevalence of Cardiovascular Risk Factors in People With Upper Vestibular Neuritis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04926363
• Other study ID #: 7665
• Status: Recruiting
• Start date: February 1, 2020
• Est. completion date: February 4, 2022

Study information

• Verified date: June 2021
• Source: University Hospital, Strasbourg, France
• Contact: Anne CHARPIOT, MD, PhD
• Phone: 33 3 88 12 76 41
• Email: anne.charpiot[@]chru-strasbourg.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Vestibular neuritis is the second cause of vertigo, it constitutes 5 to 6% of the aetiologies of vertigo in an otoneurological consultation.

Infection or reactivation of a neurotropic virus of the herpes group (HSV-1) in the vestibular lymph node is thought to be the cause of the unilateral vestibular deficit.

Upper vestibular neuritis is more common than lower, or total involvement. Goebel (2) explains this by an anatomical predisposition of the vestibular nerve canal to inflammation, unlike the singular nerve canal which is shorter and wider giving way to a certain degree of edema without consequence on its contents.

However, the innervation territory of the superior vestibular nerve is superimposable on the territory supplied by the anterior vestibular artery. The anterior, lateral semicircular canals and the utricle are affected. Current complementary vestibular and imaging examinations cannot differentiate between inflammatory or vascular involvement in upper vestibular neuritis.

The increased presence of cardiovascular risk factors in patients with upper vestibular neuritis would be an argument in favor of ischemic involvement of the anterior vestibular artery.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: February 4, 2022
• Est. primary completion date: February 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

nclusion criteria:

• Major subject (=18 years old),

• Subject having presented an episode of upper vestibular neuritis recorded on the Video Head Impulse Test Ulmer device at the HUS between 01/01/2016 and 01/31/2020,

• Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research.

Exclusion criteria:

• Patient who expressed his opposition to participating in the study,

• Total vestibular neuritis,

• impossibility of providing the subject with enlightened information (difficulties in understanding the subject, etc.)

• Subject under safeguard of justice,

• Subject under guardianship or guardianship,

• Lack of video head impulse test data.

Related Conditions & MeSH terms

• Neuritis
• Vestibular Neuritis
• Vestibular Neuronitis

Locations

Country	Name	City	State
France	Service ORL et de CCF - Hôpitaux Universitaires de Strasbourg	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Retrospective study of cardiovascular risk factors in people with upper vestibular neuritis		Files analysed retrospectively from January 01, 2016 to January 31, 2020 will be examined]